Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Hypertension II: Pathophysiology

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Adult Congenital Heart Disease Workforce Challenges in the United States: Current State and Future Needs: Proceedings from the American College of Cardiology (ACC), Adult Congenital Pediatric Cardiology (ACPC) Council Adult Congenital Heart Disease Summit.

JACC. Advances·2026

Same author

At what flow rate does the aortic valve gradient become severely elevated? Implications for guideline recommendations on aortic valve area cutoffs.

Archives of medical science : AMS·2024

Same author

Double Whammy Complicating Management of Pulmonary Hypertension.

Circulation·2024

Same author

Association of Body Mass Index With Clinical Features and Outcomes in Adults With Fontan Palliation.

Journal of the American Heart Association·2023

Same author

First in Human: Transcatheter Repair of Isolated Partial Anomalous Pulmonary Venous Return.

Circulation. Cardiovascular interventions·2022

Same author

Characterization of Potassium-Induced Natriuresis in Hypertensive Postmenopausal Women During Both Low and High Sodium Intake.

Hypertension (Dallas, Tex. : 1979)·2022

Search research articles

Related Experiment Video

Updated: May 10, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Combination therapy for hypertension 2013: an update.

Ayesha Salahuddin¹, Muzammil Mushtaq, Barry J Materson

¹Division of Hospital Medicine, Department of Medicine, University of Miami School of Medicine, Miami, FL.

Journal of the American Society of Hypertension : JASH

|June 12, 2013

Summary

Fixed-dose combination therapy for hypertension, including two- and three-drug pills, offers improved efficacy and patient adherence compared to individual components.

Keywords:

Hypertension combination therapy single-pill combinations

Related Experiment Videos

Last Updated: May 10, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Area of Science:

Cardiovascular Medicine
Pharmacology

Background:

Hypertension management requires effective and convenient treatment options.
Adherence to antihypertensive medication is crucial for controlling blood pressure.
Existing monotherapies may have limitations in efficacy or tolerability.

Purpose of the Study:

To review recent advancements in antihypertensive combination therapies.
To evaluate the efficacy and adherence benefits of single-pill combinations.
To summarize evidence supporting the use of multi-drug antihypertensive regimens.

Main Methods:

Literature review of recent studies on antihypertensive combination therapies.
Analysis of data comparing efficacy of combination pills versus individual agents.
Assessment of studies reporting patient adherence rates with fixed-dose combinations.

Main Results:

New two-drug and three-drug antihypertensive combinations in single pills are available.
Evidence indicates superior efficacy of these combination therapies over individual components.
Improved patient adherence to medication regimens has been observed with combination pills.

Conclusions:

Single-pill combination therapy represents a significant advancement in hypertension management.
These combinations enhance treatment efficacy and improve patient adherence.
Fixed-dose combination pills are a valuable strategy for optimizing blood pressure control.